The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of the mitochondrial metabolism inhibitor CPI-613 in combination with high-dose ara-C (HDAC) and mitoxantrone for relapsed or refractory acute myeloid leukemia (AML).
Timothy S. Pardee
Consultant or Advisory Role - Cornerstone Pharmaceuticals
Honoraria - Cornerstone Pharmaceuticals
Kristin Stadelman
No relevant relationships to disclose
Scott Isom
No relevant relationships to disclose
Leslie R. Ellis
No relevant relationships to disclose
Dmitriy P. Berenzon
No relevant relationships to disclose
Robin Harrelson
No relevant relationships to disclose
Megan Manuel
No relevant relationships to disclose
Sarah Dralle
No relevant relationships to disclose
Susan Lyerly
No relevant relationships to disclose
Bayard L. Powell
Consultant or Advisory Role - Cornerstone Pharmaceuticals